Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
09-12 April, 2026
Drug Discovery Chemist...Drug Discovery Chemistry
Not Confirmed
Not Confirmed
13-16 April, 2026
Not Confirmed
Not Confirmed
13-17 April, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
ICMD China
Not Confirmed
Contact SupplierICMD China
Industry Trade Show
Not Confirmed
09-12 April, 2026
Drug Discovery Chemist...Drug Discovery Chemistry
Industry Trade Show
Not Confirmed
13-16 April, 2026
Industry Trade Show
Not Confirmed
13-17 April, 2026
Digital content
NEWS #PharmaBuzz
13 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/13/3025821/0/en/Oncotelic-CEO-Vuong-Trieu-to-Present-Groundbreaking-Research-on-Transforming-Growth-Factor-Beta-2-TGFB2-at-SWCR-2025-Conference.html
08 Mar 2021
// GLOBENEWSWIRE
http://www.globenewswire.com/news-release/2021/03/08/2188544/0/en/MATEON-S-UPDATE-ON-C001-GLOBAL-STUDY-FOR-OT-101-AGAINST-COVID-19.html
30 Dec 2020
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2020/12/30/2151812/0/en/MATEON-S-GLOBAL-STUDY-FOR-OT-101-TGF-%CE%B2-INHIBITOR-AGAINST-COVID-19-ENROLLS-AND-TREATS-ITS-FIRST-PATIENT.html
16 Sep 2020
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2020/09/16/2094584/0/en/FDA-Granted-Pediatric-Disease-Designation-for-OXi-4503.html
20 Jul 2020
// BIOSPACE
https://www.biospace.com/article/releases/mateon-and-asili-research-alliance-enter-into-partnership-for-the-development-of-artemisinin-against-covid-19/
13 Jul 2020
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2020/07/13/2061115/0/en/Mateon-Therapeutics-to-fund-observational-studies-of-Artemisinin-in-developing-countries.html
Drugs in Development
Details:
Teon Therapeutics has entered into the clinical trial collaboration agreement with Merck for expansion clinical study and will evaluate Teon’s oral, immune response modifier, TT-816, in combination with Merck’s KEYTRUDA (pembrolizumab), for patients with advanced solid tumors.
Lead Product(s): TT-816,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 18, 2023
Lead Product(s) : TT-816,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Teon Therapeutics has entered into the clinical trial collaboration agreement with Merck for expansion clinical study and will evaluate Teon’s oral, immune response modifier, TT-816, in combination with Merck’s KEYTRUDA (pembrolizumab), for patients ...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 18, 2023
Details:
TT-816 is a first-in-class, oral cannabinoid CB2 receptor antagonist acting as an immune checkpoint inhibitor for the treatment of a broad range of solid tumors and is highly selective for the CB2 receptor versus the CB1 receptor.
Lead Product(s): TT-816,Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 01, 2022
Lead Product(s) : TT-816,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TT-816 is a first-in-class, oral cannabinoid CB2 receptor antagonist acting as an immune checkpoint inhibitor for the treatment of a broad range of solid tumors and is highly selective for the CB2 receptor versus the CB1 receptor.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 01, 2022
Details:
Anti-viral activity OT-101 (trabedersen), in an in vitro antiviral testing which has a 50% effective concentration of 7.6 µg/mL and is not toxic at highest dose of 1000 µg/mL giving safety index value of >130, is considered highly active and on par or superior to Remdesivir.
Lead Product(s): Trabedersen
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Oligonucleotide
Recipient: Oncotelic Therapeutics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 28, 2022
Lead Product(s) : Trabedersen
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Oncotelic Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Anti-viral activity OT-101 (trabedersen), in an in vitro antiviral testing which has a 50% effective concentration of 7.6 µg/mL and is not toxic at highest dose of 1000 µg/mL giving safety index value of >130, is considered highly active and on par or ...
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
September 28, 2022
Details:
Artemisinin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of COVID-19.
Lead Product(s): Artemisinin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Windlas Biotech
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 13, 2021
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Windlas Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Artemisinin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 13, 2021
Details:
Mateon has completed the enrollment of its sentinel Part 1 and Part 2 COVID-19 patients which allows for the continuing expansion to the targeted 18 patients in part 1 and 18 patients in part 2. OT-101 is an antisense against the host TGF-β protein.
Lead Product(s): Trabedersen,Artemisinin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Oligonucleotide
Sponsor: Oncotelic Therapeutics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 08, 2021
Lead Product(s) : Trabedersen,Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Oncotelic Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Mateon’s Update on C001 - Global Study for Ot-101 Against Covid-19
Details : Mateon has completed the enrollment of its sentinel Part 1 and Part 2 COVID-19 patients which allows for the continuing expansion to the targeted 18 patients in part 1 and 18 patients in part 2. OT-101 is an antisense against the host TGF-β protein.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 08, 2021
Details:
The funds will be used to advance the company’s lead A2BR-selective antagonist TT-702 into the clinic as well as to build the company’s pipeline.
Lead Product(s): TT-702
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Miscellaneous
Sponsor: Oceanpine Capital
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 23, 2021
Lead Product(s) : TT-702
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Oceanpine Capital
Deal Size : $30.0 million
Deal Type : Series A Financing
Teon Therapeutics Completes $30 Million Series A Financing
Details : The funds will be used to advance the company’s lead A2BR-selective antagonist TT-702 into the clinic as well as to build the company’s pipeline.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 23, 2021
Details:
C-001 is a Phase 2 randomized, placebo-control study to evaluate safety and efficacy of OT-101 in combination with standard of care on two patient cohorts – 1) mild or moderate disease, and 2) severe disease requiring mechanical ventilation or intubation.
Lead Product(s): Trabedersen,Undisclosed
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 30, 2020
Lead Product(s) : Trabedersen,Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Mateon’s Global Study for OT-101/ Tgf-Β Inhibitor Against Covid-19 Enrolls and Treats Its First...
Details : C-001 is a Phase 2 randomized, placebo-control study to evaluate safety and efficacy of OT-101 in combination with standard of care on two patient cohorts – 1) mild or moderate disease, and 2) severe disease requiring mechanical ventilation or intubati...
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
December 30, 2020
Details:
OXi4503 in combination with standard chemotherapy drug cytarabine was generally well tolerated by adult AML patients and a maximum tolerated dose level of OXi4503 was identified as the recommended dose for further clinical development of this novel two-drug combination.
Lead Product(s): Combretastatin A1 Diphosphate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 16, 2020
Lead Product(s) : Combretastatin A1 Diphosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Granted Pediatric Disease Designation for OXi-4503
Details : OXi4503 in combination with standard chemotherapy drug cytarabine was generally well tolerated by adult AML patients and a maximum tolerated dose level of OXi4503 was identified as the recommended dose for further clinical development of this novel two-d...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 16, 2020
Details:
ARTI19 is designed to rapidly establish the clinical efficacy of Artemisinin in mild and moderate COVID-19 patients. In-vitro, the medical grade version of the supplement has proven potency and safety similar to Remdesivir with an EC50 = 0.45 ug/ml and Safety Index = 140.
Lead Product(s): Artemisinin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Recipient: Asili Research Alliance
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 20, 2020
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Asili Research Alliance
Deal Size : Undisclosed
Deal Type : Partnership
Details : ARTI19 is designed to rapidly establish the clinical efficacy of Artemisinin in mild and moderate COVID-19 patients. In-vitro, the medical grade version of the supplement has proven potency and safety similar to Remdesivir with an EC50 = 0.45 ug/ml and S...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 20, 2020
Details:
Mateon Therapeutics announced that it will fund observational studies for Artemisinin, an herbal supplement, that demonstrated potent in vitro activity against SARS-CoV-2, the COVID-19 virus.
Lead Product(s): Artemisinin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Recipient: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding July 13, 2020
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Undisclosed
Deal Size : Undisclosed
Deal Type : Funding
Mateon Therapeutics to Fund Observational Studies of Artemisinin in Developing Countries
Details : Mateon Therapeutics announced that it will fund observational studies for Artemisinin, an herbal supplement, that demonstrated potent in vitro activity against SARS-CoV-2, the COVID-19 virus.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
Share 
